Disease Domain | Count |
---|---|
Nervous System Diseases | 4 |
Neoplasms | 4 |
Endocrinology and Metabolic Disease | 2 |
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 15 |
Diagnostic radiopharmaceuticals | 11 |
Contrast agent | 2 |
Peptide drug conjugates | 1 |
Radiopharmaceuticals and diagnostic agent | 1 |
Target |
Mechanism Mcl-1 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Sep 2024 |
Target |
Mechanism ERs antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 May 2020 |
Target |
Mechanism APP inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Oct 2013 |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date30 Nov 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator Mayo Clinic [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Gadodiamide | Contrast agents More | Approved |
Fluoroestradiol F 18 ( ER ) | Metastatic breast cancer More | Approved |
Perflutren protein-type A microspheres(GE healthcare) | Heart Diseases More | Approved |
Flurpiridaz F 18 ( Mcl-1 x NQO1 ) | Coronary Artery Disease More | Approved |
Ioflupane-I-123 ( DAT ) | Lewy Body Disease More | Approved |